Illumina Launches TruSight Tumor 170
November 07 2016 - 8:00AM
Business Wire
Newest Addition in Clinical Cancer Research
Portfolio Aims to Establish a Standardized Method for Tumor
Profiling
Illumina, Inc. (NASDAQ:ILMN) today announced the launch of
TruSight® Tumor 170, a 170 gene next-generation sequencing solution
to support the transformation of the tumor-profiling paradigm from
a series of single-gene tests to a multi-analyte approach,
providing a more thorough picture of a tumor’s genomic
landscape.
TruSight Tumor 170 offers an integrated DNA and RNA
enrichment-based workflow, targeting cancer-related genetic
aberrations, including small variants, gene amplifications, gene
fusions, and splice variants. With optimized bioinformatics tools
and automation options, laboratories can implement the assay on an
in-house, research use only NextSeq® instrument. Designed to
support limited nucleic acid input from formalin-fixed,
paraffin-embedded (FFPE) samples, TruSight Tumor 170 facilitates
efficient evaluation of biomarkers.
“Having broader gene content allows us to improve cancer
research by assessing more genes and to identify structural
alterations that are important targets for developing therapies,”
said pathologist Anthony Magliocco. “We hope these capabilities
will improve clinical cancer research by streamlining the testing
of solid tumors. Due to the flexibility of the enrichment
methodology upon which TruSight Tumor 170 is based, this technology
has the potential to serve as a platform for many applications
beyond solid tumor profiling.”
“This new assay is poised to help realize the potential of
precision oncology,” said John Leite, PhD, Vice President of
Oncology at Illumina. “By integrating DNA and RNA into one
protocol, clinical researchers are able to accelerate comprehensive
analysis of cancer-related variants and maximize the data
obtainable from precious specimens. Looking forward, we aim to
deploy the underlying assay method at the heart of TruSight Tumor
170 as a universal standard for optimized tissue assessment across
a variety of applications with both fixed and customizable
panels.”
“We’re committed to delivering the tools that enable a shared
vision of personalized oncology,” said Francis deSouza, President
and CEO of Illumina. “We believe the introduction of TruSight Tumor
170 will enable research insights that will positively impact
cancer patients in the future.”
TruSight Tumor 170 offers broader investigational
power:
- Enrichment-based assay that evaluates
DNA and RNA in one integrated protocol
- 170 unique genes informed by partnering
pharmaceutical companies, academic community leaders, and industry
guidance
- Integrated workflow requires only 40ng
of DNA and RNA from FFPE samples, allowing more comprehensive
testing while preserving precious samples
- Underlying assay method to serve as a
standard for optimized tissue assessment across a variety of
applications
TruSight Tumor 170 will begin shipping in Q1 2017. For more
information, please visit www.illumina.com/TruSightTumor170.
For Research Use Only. Not for use in diagnostic
procedures.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical, and applied
markets. Our products are used for applications in the life
sciences, oncology, reproductive health, agriculture, and other
emerging segments. To learn more, visit www.illumina.com and follow
@illumina.
Use of forward-looking statements
This release contains projections, information about our
financial outlook, earnings guidance, and other forward-looking
statements that involve risks and uncertainties. These
forward-looking statements are based on our expectations as of the
date of this release and may differ materially from actual future
events or results. Among the important factors that could cause
actual results to differ materially from those in any
forward-looking statements are (i) our ability to further develop
and commercialize our instruments and consumables and to deploy new
products, services and applications, and expand the markets for our
technology platforms; (ii) our ability to manufacture robust
instrumentation and consumables; (iii) our ability to successfully
identify and integrate acquired technologies, products or
businesses; (iv) the future conduct and growth of the business and
the markets in which we operate; (v) challenges inherent in
developing, manufacturing, and launching new products and services;
and (vi) the application of generally accepted accounting
principles, which are highly complex and involve many subjective
assumptions, estimates, and judgments, together with other factors
detailed in our filings with the Securities and Exchange
Commission, including our most recent filings on Forms 10-K and
10-Q, or in information disclosed in public conference calls, the
date and time of which are released beforehand. We undertake no
obligation, and do not intend, to update these forward-looking
statements, to review or confirm analysts’ expectations, or to
provide interim reports or updates on the progress of the current
quarter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161107005280/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243IR@illumina.comorMedia:Jen Carroll,
858-882-6822PR@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024